Cybin (NASDAQ:HELP) Price Target Raised to $95.00 at HC Wainwright

Cybin (NASDAQ:HELP) had its price target upped by analysts at HC Wainwright from $55.00 to $95.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock.

Separately, Jefferies Financial Group assumed coverage on shares of Cybin in a research note on Monday, February 2nd. They issued a “buy” rating and a $22.00 price objective for the company. Two analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Cybin has an average rating of “Buy” and an average target price of $58.50.

Cybin Stock Down 1.4%

NASDAQ:HELP opened at $7.25 on Monday. Cybin has a 1-year low of $4.81 and a 1-year high of $9.83. The stock has a market capitalization of $362.79 million, a P/E ratio of -1.71 and a beta of 0.61.

Cybin (NASDAQ:HELP) last posted its earnings results on Friday, February 13th. The company reported ($0.72) EPS for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.19).

About Cybin

Cybin Inc is a clinical-stage biopharmaceutical company focused on the development of psychedelic-based therapeutics for the treatment of mental health disorders. Headquartered in Toronto and listed on the NASDAQ under the symbol HELP, Cybin pursues research and development programs intended to harness the therapeutic potential of psychedelic compounds to address conditions with significant unmet need.

The company operates a drug discovery and development platform aimed at creating novel small-molecule psychedelic analogs and tailored formulations.